# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



Approved for use through 10/31/2002, OMB 0851-0032 U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)	
Title of <b>invention</b>	PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF BETA-CATENIN SIGNALING PATHWAYS
As the below named	Inventor(s), I/we declare that:
This declaration is d	irected to:
	The attached application, or Application No. 10/7/29 548, filed on December 5, 2003.
	as amended on (if applicable);
I/we believe that I/w patent is sought;	re am/are the original and first inventor(s) of the subject matter which is claimed and for which a
live have reviewed by any amendment	and understand the contents of the above-identified application, including the claims, as amended specifically referred to above;
Mendo to be marada	ne duly to disclose to the United States Patent and Trademark Office all Information known to to patentability as defined in 37 CFR 1.56, including material information which became available ate of the prior application and the national or PCT international filing date of the continuation-in- plicable; and.
and the like are puni	herein of my/our own knowledge are true, all statements made herein on information and belief tie, and further that these statements were made with the knowledge that willful false statements shable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of y patent issuing thereon.
As a named inventor to prosecute the app Office connected the	I hereby appoint Practitioners at Customer Number 24353 as my/our attorney(s) or agent(s) lication identified above, and to transact all business in the United States Patent and Trademark rewith
FULL NAME OF INV	
Inventor one: WEIS:	CHESON OF USA
Inventor two: REYA	TANNISHTHA .
Signature:	Cilizen of:
Additional Inventors a	re being named on additional form(s) attached hereto.

Burden Hour Statement: This occleation of information is required by 35 U.S.C. 125 and 37 CFR 1.83. The information is used by the public to file ( and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to cate 1 minute to complete. This time will vary depending upon the needs of the individual case. Any continents on the amount of time you are required to complete (its form should be sent to the Chief information, U.S. Patient and Trademark Office, Washington, DC 20231. DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant

F1DOCUMENT/STAN (Stanford)/270US2\documentur.dus

PTO/SB/01a (10-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

approved: Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)** PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF BETA-CATENIN Title of Invention SIGNALING PATHWAYS As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No. 10/729,548 filed on December 5, 2003, as amended on \_\_\_\_ (if applicable); I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought; I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-inpart application, if applicable; and. All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon. As a named inventor I hereby appoint Practitioners at Customer Number 24353 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith **FULL NAME OF INVENTOR(S)** Inventor one: WEISSMAN, IRVING L. Signature: Citizen of: Signature: additional form(s) attached hereto.

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file ( and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.